Why These 15 Healthcare Stocks Are Surging in 2025

Page 5 of 14

10. GRAIL Inc (NASDAQ:GRAL)

Number of Hedge Fund Holders In Q4 2024: 28

GRAIL Inc (NASDAQ:GRAL) is a biotechnology company focused on early cancer detection through its Galleri multi-cancer early detection blood test, which uses next-generation sequencing and machine learning to identify cancer signals from a simple blood draw.

The stock has soared in 2025, with the most significant boost coming after the announcement that TRICARE, one of the largest US health plans, would cover the Galleri test for adults over 50 at elevated cancer risk.

This coverage decision dramatically expanded the test’s addressable market and validated GRAIL’s commercial strategy, leading to a sharp increase in investor interest. GRAIL also reported strong financial results, with 2024 revenue up 35% year-over-year to $125.6 million and Galleri test revenue up 45% to $108.6 million.

In February 2025, GRAIL announced a partnership with Quest Diagnostics to integrate Galleri into Quest’s national test ordering system, further expanding access and distribution. The company completed major registrational studies in July 2024 and plans to submit for FDA approval in 2026.

The consensus price target of $26 implies 30.1% downside.

GRAL stock is up 108.40% year-to-date.

Page 5 of 14